ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Artiva Biotherapeutics Inc

Artiva Biotherapeutics Inc (ARTV)

10,06
-0,45
(-4,28%)
Fermé 17 Novembre 10:00PM
10,05
-0,01
(-0,10%)
Après les heures de négociation: 1:59AM

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
10,06
Prix Achat
9,13
Prix Vente
12,10
Volume échangé
97 374
10,01 Fourchette du Jour 10,93
9,68 Plage de 52 semaines 17,31
Cap du marché
Clôture Veille
10,51
Ouverture
10,93
Dernière Transaction
8
@
10.26
Dernière heure de transaction
Volume financier
US$ 1 011 548
VWAP
10,3883
Volume moyen (3 m)
144 235
Actions en circulation
24 287 144
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-8,50
Bénéfice par action (BPA)
-1,18
Chiffre d'affairess
33,49M
Bénéfice net
-28,72M

À propos de Artiva Biotherapeutics Inc

Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (... Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patients treatment location, making them what we believe to be off-the-shelf. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Siège social
Dover, Delaware, USA
Fondé
-
Artiva Biotherapeutics Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker ARTV. Le dernier cours de clôture d'Artiva Biotherapeutics était de US$10,51. Au cours de la dernière année, les actions de Artiva Biotherapeutics ont été négociées dans une fourchette de prix de US$ 9,68 à US$ 17,31.

Artiva Biotherapeutics compte actuellement 24 287 144 actions en circulation. La capitalisation boursière d'Artiva Biotherapeutics est de US$255,26 million. Artiva Biotherapeutics a un ratio cours/bénéfice (ratio PE) de -8.50.

ARTV Dernières nouvelles

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune...

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK®...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-3.94-28.14285714291414.2210.055505912.54669081CS
4-2.7-21.159874608212.7615.499.686366711.70956549CS
120.060.61017.319.6814423512.48282471CS
26-5.94-37.1251617.319.6814340812.20069786CS
52-5.94-37.1251617.319.6814340812.20069786CS
156-5.94-37.1251617.319.6814340812.20069786CS
260-5.94-37.1251617.319.6814340812.20069786CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
CEROCERo Therapeutics Holdings Inc
US$ 0,2853
(52,40%)
1,17B
CYCNCyclerion Therapeutics Inc
US$ 2,5306
(42,97%)
11,99M
SPPLSIMPPLE Ltd
US$ 1,2503
(41,60%)
165,69M
PULMPulmatrix Inc
US$ 6,5586
(39,54%)
5,37M
ZTEKZentek Ltd
US$ 1,2574
(29,96%)
309,67k
TFFPTFF Pharmaceuticals Inc
US$ 0,376101
(-76,49%)
9,35M
EYENEyenovia Inc
US$ 0,10185
(-70,05%)
52,8M
CTXRCitius Pharmaceuticals Inc
US$ 0,1974
(-39,89%)
11,26M
VVPRVivoPower International PLC
US$ 0,8151
(-39,62%)
2,34M
IPWiPower Inc
US$ 0,7302
(-39,15%)
1,15M
CEROCERo Therapeutics Holdings Inc
US$ 0,2853
(52,40%)
1,15B
ELABElevai Labs Inc
US$ 0,0211
(-19,47%)
377,69M
NVDANVIDIA Corporation
US$ 141,98
(-3,26%)
244,07M
SPPLSIMPPLE Ltd
US$ 1,2503
(41,60%)
164,49M
STISolidion Technology Inc
US$ 0,44
(25,71%)
139,46M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock